老年CHF患者血清sVEGFR-2、TRPC1、Nesfatin-1水平变化及临床意义  

Changes and clinical significance of serum levels of sVEGFR-2,TRPC1,and Nesfatin-1 in elderly patients with CHF

作　　者：左彦超 武永华 陈鲜 季会娟 ZUO Yanchao;WU Yonghua;CHEN Xian;JI Huijuan(Department of Diabetes and Geriatrics,Puyang Hospital of Traditional Chinese Medicine,Puyang 457001,China)

机构地区：[1]濮阳市中医医院糖尿病老年病科,濮阳457001

出　　处：《华夏医学》2025年第2期116-121,共6页Acta Medicinae Sinica

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20211102)。

摘　　要：目的探讨老年慢性心力衰竭(CHF)患者血清可溶性血管内皮生长因子受体-2(sVEGFR-2)、瞬时受体电位通道1(TRPC1)、摄食抑制因子1(Nesfatin-1)水平的变化及临床意义。方法回顾性选取我院126例CHF患者,依据纽约心脏病协会(NYHA)分级,分别纳入Ⅱ级组、Ⅲ级组、Ⅳ级组。比较3组sVEGFR-2、TRPC1、Nesfatin-1及左房内径(LAD)、左心室舒张末内径(LVEDD)、左室射血分数(LVEF)并分析相关性,比较不同预后患者sVEGFR-2、TRPC1、Nesfatin-1及联合检测对老年CHF患者预后的预测价值。结果Ⅱ级组sVEGFR-2、TRPC1、LAD、LVEDD<Ⅲ级组<Ⅳ级组,Nesfatin-1、LVEF>Ⅲ级组>Ⅳ级组,差异有统计学意义(P<0.05);sVEGFR-2、TRPC1与NYHA分级、LAD、LVEDD呈正相关,与LVEF呈负相关,Nesfatin-1与LAD、LVEDD、NYHA分级呈负相关,与LVEF呈正相关,差异有统计学意义(P<0.05);预后不良患者sVEGFR-2、TRPC1高于预后良好患者,Nesfatin-1低于预后良好患者(P<0.05);sVEGFR-2、TRPC1、Nesfatin-1联合预测预后不良的AUC高于各指标单独检测(P<0.05)。结论sVEGFR-2、TRPC1、Nesfatin-1随着NYHA分级、心脏功能异常而改变,三者联合可为预测老年CHF患者预后提供参考价值。Objective To investigate the changes and clinical significance of soluble vascular endothelial growth factor receptor-2(sVEGFR-2),transient receptor potential channel 1(TRPC1),and neuropeptide Y-1 receptor(Nesfatin-1)levels in elderly patients with chronic heart failure(CHF).Methods 126 patients with CHF in our hospital were retrospectively selected.According to the New York Heart Association(NYHA)classification,the patients with CHF were divided into three groups:the gradeⅡgroup,gradeⅢgroup,and gradeⅣgroup.The levelss of serum sVEGFR-2,TRPC1 and Nesfatin-1,left atrial diameter(LAD),left ventricular end-diastolic diameter(LVEDD),and left ventricular ejection fraction(LVEF)were compared among the three groups,and the correlation was analyzed.The prognostic value of serum sVEGFR-2,TRPC1 and Nesfatin-1 levels,and their combined detection was compared in predicting the prognosis of elderly patients with CHF.Results The levels of serum sVEGFR-2 and TRPC1,LAD and LVEDD in the gradeⅡgroup<gradeⅢgroup<gradeⅣgroup,and the levels of Nesfatin-1 and LVEF in the gradeⅡgroup>gradeⅢgroup>gradeⅣgroup,showing a statistically significant difference(P<0.05).The sVEGFR-2 and TRPC1 were positively correlated with the NYHA classification,LAD and LVEDD,and were negatively correlated with the LVEF.The levels of serum Nesfatin-1 was negatively correlated with the LAD,LVEDD and NYHA classification,and was positively correlated with the LVEF(P<0.05).The levels of serum sVEGFR-2 and TRPC1 were higher and the levels of serum Nesfatin-1 in the patients with poor prognosis was lower than those in the patients with good prognosis(P<0.05).The AUC of sVEGFR-2,TRPC1,and Nesfatin-1 combined to predict poor prognosis was higher than that in each indicator alone(P<0.05).Conclusion sVEGFR-2,TRPC1,and Nesfatin-1 change with NYHA classification and cardiac dysfunction,and their combination provides reference value for predicting the prognosis in elderly patients with CHF.

关 键 词：慢性心力衰竭 sVEGFR-2 TRPC1 NESFATIN-1 老年人 

分 类 号：R541.6[医药卫生—心血管疾病]